Skip to main content
SIU School of Medicine Logo

Domain Menu

  • Patient Care
  • School of Medicine

Main Menu Edu Secondary

  • faculty
  • intranet
  • library
  • news & events
  • donate
  • careers
I am a...
  • Patient
  • Donor or Friend
  • Prospective Employee
  • Student/Prospective Student
  • Resident or Fellow
  • Alumni

Main Menu Edu

Main Menu Close
Main Menu
  • Degree Programs
  • Research
  • Academic & Clinical Departments
  • Centers & Institutes
  • Community Programs
    • Equity, Diversity and Inclusion
    • External Relations
    • Family and Community Medicine
    • Office of Community Care
    • Office of Correctional Medicine
    • Population Science and Policy
    • Rural Health and Social Service Development
  • About Us
    • Administrative offices
    • Careers
    • Why SIU School of Medicine
      • Strategic plan
      • A Model for Medical Education
      • Facts and figures
      • Our campuses
    • Economic Impact Report (pdf)
    • History
      • Notable alumni
      • Points of pride
      • Timeline
    • Leadership
      • SIU Medicine Board of Directors
      • SIU School of Medicine Leadership
    • News and Events

Group Menu

Main Menu Close Main Menu Close
Main Menu
  • Internal Medicine
  • About Us
    • Faculty
    • Current Residents
    • Faculty Administration
    • Work Environment
  • Divisions
    • Cardiology
    • Dermatology
    • Endocrinology
    • Gastroenterology
    • General Internal Medicine
    • Infectious Diseases
    • Pulmonary and Critical Care
    • Rheumatology
  • Education
    • Internal Medicine Residency Program
    • Residency Application
    • Resident Scholarly Activity
    • Clerkship
    • Fellowships
  • Research
    • Clinical and Translational Science Group
    • Geriatrics Research
Search Site close Close

Breadcrumb

  1. Home
  2. AstraZeneca BaxHTN: A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypert

The purpose of this clinical trial is to trial is to learn more about a new, investigational, once daily medication, called baxdrostat, and its ability to lower blood pressure in individuals not responding to their current treatment.

Research
Patient
Internal Medicine
Active, not recruiting
Internal Medicine
217-545-7616
Related Profiles
John Flack
estarkey74@siumed.edu
Emily Starkey
https://clinicaltrials.gov/study/NCT06034743?term=baxdrostat&rank=3

This browser is no longer supported and some key features will not work. We strongly recommend using Edge, Chrome 70+, Safari 5.x+ and Firefox 5.x+.

SIU School of Medicine Logo
© 2025 SIU Board of Trustees all rights reserved

Legal

  • Equal Opportunity Employer
  • Nondiscrimination Statement
  • Privacy Policy
  • FOIA
  • ADA

About Us

  • About Us
  • Contact
  • SIU Intranet
  • SIU Medicine
  • Southern Illinois University Carbondale
  • Southern Illinois University Edwardsville
  • Southern Illinois University System

Social

  • Facebook
  • Twitter
  • Youtube
  • Instagram